Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Details

Language :

English

ISSN :

0732183X

Volume :

27

Issue :

17

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

105352864

Full Text :

https://doi.org/10.1200/JCO.2007.15.7636